Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the FRESH-UP ...

Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heartfailure-related health status (KCCQ) in ...

据悉，EDG-7500是一种创新口服选择性心脏肌节调节剂，专门设计用于减缓早期收缩速度，并解决与HCM相关的心脏舒张受损问题。RBC表示，如果EDG-7500在单次递增剂量(SAD)试验中的数据显示出在梯度降低上有所改善，同时也显示出功能改善(如用于评估心力衰竭(HF ...

SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin ...

Diastolic dysfunction is a heart condition that happens when there is a “stiffening” of the major pumping chambers of the organ (ventricles). This stiffness gets in the way of the heart’s ability to ...

Ventricular tachycardia is an abnormally fast heart beat (with three or more consecutive heart beats at least 100 beats per minute) that originates from one of the ventricles in the heart.

Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the ...